Fatal fulminant hepatitis associated with bromfenac use

John M. Rabkin, Megan J. Smith, Susan Orloff, Christopher Corless, Peter Stenzel, Ali J. Olyaei

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

OBJECTIVE: To report a case of fulminant hepatic failure associated with the use of bromfenac, a new analog of the phenyl acetate class of nonsteroidal antiinflammatory drugs. CASE SUMMARY: A 60-year-old white woman with liver failure who had no known history of chronic liver disease was transferred to the liver transplant unit for evaluation. For three months preceding her illness, the patient was treated with bromfenac 25 mg po qid for arthritic pain. Prior to the initiation of bromfenac, her liver function test results were normal. Etiologic evaluation at presentation was unremarkable. The patient's condition continued to deteriorate, with the development of hepatic encephalopathy and worsening liver function test results while awaiting liver transplantation. Progressive hepatic and renal dysfunction along with respiratory decompensation ensued, and the patient died 48 days after initial presentation. CONCLUSIONS: Fulminant hepatic failure associated with the prolonged use of bromfenac appears to be an idiosyncratic response consistent with experience with other agents of its class. This case along with other cases of serious hepatotoxicity associated with the use of this agent ultimately resulted in bromfenac's removal from the market.

Original languageEnglish (US)
Pages (from-to)945-947
Number of pages3
JournalAnnals of Pharmacotherapy
Volume33
Issue number9
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Hepatitis
Acute Liver Failure
Liver Function Tests
Hepatic Encephalopathy
Liver
Liver Failure
Liver Transplantation
Arthritis
Liver Diseases
Chronic Disease
Anti-Inflammatory Agents
bromfenac
Transplants
Kidney
Pain
Pharmaceutical Preparations

Keywords

  • Bromfenac
  • Hepatic failure

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Fatal fulminant hepatitis associated with bromfenac use. / Rabkin, John M.; Smith, Megan J.; Orloff, Susan; Corless, Christopher; Stenzel, Peter; Olyaei, Ali J.

In: Annals of Pharmacotherapy, Vol. 33, No. 9, 1999, p. 945-947.

Research output: Contribution to journalArticle

Rabkin, John M. ; Smith, Megan J. ; Orloff, Susan ; Corless, Christopher ; Stenzel, Peter ; Olyaei, Ali J. / Fatal fulminant hepatitis associated with bromfenac use. In: Annals of Pharmacotherapy. 1999 ; Vol. 33, No. 9. pp. 945-947.
@article{aa7847b1b84046f3a3ba2373295b8482,
title = "Fatal fulminant hepatitis associated with bromfenac use",
abstract = "OBJECTIVE: To report a case of fulminant hepatic failure associated with the use of bromfenac, a new analog of the phenyl acetate class of nonsteroidal antiinflammatory drugs. CASE SUMMARY: A 60-year-old white woman with liver failure who had no known history of chronic liver disease was transferred to the liver transplant unit for evaluation. For three months preceding her illness, the patient was treated with bromfenac 25 mg po qid for arthritic pain. Prior to the initiation of bromfenac, her liver function test results were normal. Etiologic evaluation at presentation was unremarkable. The patient's condition continued to deteriorate, with the development of hepatic encephalopathy and worsening liver function test results while awaiting liver transplantation. Progressive hepatic and renal dysfunction along with respiratory decompensation ensued, and the patient died 48 days after initial presentation. CONCLUSIONS: Fulminant hepatic failure associated with the prolonged use of bromfenac appears to be an idiosyncratic response consistent with experience with other agents of its class. This case along with other cases of serious hepatotoxicity associated with the use of this agent ultimately resulted in bromfenac's removal from the market.",
keywords = "Bromfenac, Hepatic failure",
author = "Rabkin, {John M.} and Smith, {Megan J.} and Susan Orloff and Christopher Corless and Peter Stenzel and Olyaei, {Ali J.}",
year = "1999",
doi = "10.1345/aph.18364",
language = "English (US)",
volume = "33",
pages = "945--947",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "9",

}

TY - JOUR

T1 - Fatal fulminant hepatitis associated with bromfenac use

AU - Rabkin, John M.

AU - Smith, Megan J.

AU - Orloff, Susan

AU - Corless, Christopher

AU - Stenzel, Peter

AU - Olyaei, Ali J.

PY - 1999

Y1 - 1999

N2 - OBJECTIVE: To report a case of fulminant hepatic failure associated with the use of bromfenac, a new analog of the phenyl acetate class of nonsteroidal antiinflammatory drugs. CASE SUMMARY: A 60-year-old white woman with liver failure who had no known history of chronic liver disease was transferred to the liver transplant unit for evaluation. For three months preceding her illness, the patient was treated with bromfenac 25 mg po qid for arthritic pain. Prior to the initiation of bromfenac, her liver function test results were normal. Etiologic evaluation at presentation was unremarkable. The patient's condition continued to deteriorate, with the development of hepatic encephalopathy and worsening liver function test results while awaiting liver transplantation. Progressive hepatic and renal dysfunction along with respiratory decompensation ensued, and the patient died 48 days after initial presentation. CONCLUSIONS: Fulminant hepatic failure associated with the prolonged use of bromfenac appears to be an idiosyncratic response consistent with experience with other agents of its class. This case along with other cases of serious hepatotoxicity associated with the use of this agent ultimately resulted in bromfenac's removal from the market.

AB - OBJECTIVE: To report a case of fulminant hepatic failure associated with the use of bromfenac, a new analog of the phenyl acetate class of nonsteroidal antiinflammatory drugs. CASE SUMMARY: A 60-year-old white woman with liver failure who had no known history of chronic liver disease was transferred to the liver transplant unit for evaluation. For three months preceding her illness, the patient was treated with bromfenac 25 mg po qid for arthritic pain. Prior to the initiation of bromfenac, her liver function test results were normal. Etiologic evaluation at presentation was unremarkable. The patient's condition continued to deteriorate, with the development of hepatic encephalopathy and worsening liver function test results while awaiting liver transplantation. Progressive hepatic and renal dysfunction along with respiratory decompensation ensued, and the patient died 48 days after initial presentation. CONCLUSIONS: Fulminant hepatic failure associated with the prolonged use of bromfenac appears to be an idiosyncratic response consistent with experience with other agents of its class. This case along with other cases of serious hepatotoxicity associated with the use of this agent ultimately resulted in bromfenac's removal from the market.

KW - Bromfenac

KW - Hepatic failure

UR - http://www.scopus.com/inward/record.url?scp=0032863690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032863690&partnerID=8YFLogxK

U2 - 10.1345/aph.18364

DO - 10.1345/aph.18364

M3 - Article

C2 - 10492497

AN - SCOPUS:0032863690

VL - 33

SP - 945

EP - 947

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 9

ER -